AquaVac PD3 Emulsion for Injection, for Atlantic Salmon

Authorised

- Salmon pancreas disease virus, strain F93-125, Inactivated
- Infectious pancreatic necrosis virus, Inactivated
- Aeromonas salmonicida, subsp. salmonicida, Inactivated

Product identification

Medicine name:
AquaVac PD3 emulsion for injection for Atlantic salmon
AquaVac PD3 Emulsion for Injection, for Atlantic Salmon

Active substance:
Salmon pancreas disease virus, strain F93-125, Inactivated
Infectious pancreatic necrosis virus, Inactivated
Aeromonas salmonicida, subsp. salmonicida, Inactivated

Target species:
Atlantic salmon

Route of administration:
Intraperitoneal use

Product details

Active substance and strength:

Salmon pancreas disease virus, strain F93-125, Inactivated

Infectious pancreatic necrosis virus, Inactivated
1.50 enzyme-linked immunosorbent assay unit / 1.00 Dose

Aeromonas salmonicida, subsp. salmonicida, Inactivated
80.00 Relative Percentage Survival / 1.00 Dose

Pharmaceutical form:
Emulsion for injection

Withdrawal period by route of administration:
Intraperitoneal use:

- **Atlantic salmon**
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI10AL

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
United Kingdom (Northern Ireland)

Package description:
Bottles of polyethylene terephthalate (PET) closed with a rubber stopper and aluminium cap.Package size: 500 ml (5,000 doses).

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
26/03/2015

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
The Veterinary Medicines Directorate

Authorisation number:
Vm 06376/3056

Date of authorisation status change:
14/11/2023

Reference member state:
Ireland

Procedure number:
IE/V/0339/001

Concerned member states:
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents